Enterobacter aerogenes

Authority:{{{subdivision_ranks}}}:

Enterobacter aerogenes
Kingdom:
Phylum:	Pseudomonadota
Class:	Gammaproteobacteria
Order:	Enterobacterales
Family:	Enterobacteriaceae

Enterobacter aerogenes is a Gram-negative bacterium belonging to the family Enterobacteriaceae. It is a facultative anaerobe and is commonly found in the gastrointestinal tract of humans and animals. E. aerogenes is known for its role in nosocomial infections and its ability to develop antibiotic resistance.

Morphology and Identification

Enterobacter aerogenes is a rod-shaped bacterium that measures approximately 1-3 micrometers in length. It is motile due to the presence of peritrichous flagella. The bacterium is non-spore-forming and exhibits facultative anaerobic metabolism.

In laboratory settings, E. aerogenes can be identified using various biochemical tests. It is lactose-fermenting and produces gas during fermentation. On MacConkey agar, it forms pink colonies due to lactose fermentation. It is also positive for the Voges-Proskauer test, indicating the production of acetoin.

Habitat and Ecology

Enterobacter aerogenes is commonly found in the environment, including soil, water, and sewage. It is also a part of the normal microbiota of the human intestine. The bacterium can survive in a variety of environments due to its metabolic versatility.

Pathogenicity

Enterobacter aerogenes is an opportunistic pathogen, primarily causing infections in immunocompromised individuals. It is associated with a range of nosocomial infections, including urinary tract infections, respiratory tract infections, wound infections, and bacteremia.

The pathogenicity of E. aerogenes is attributed to several virulence factors, including the production of capsules, lipopolysaccharides, and adhesins. These factors enable the bacterium to evade the host's immune system and establish infections.

Antibiotic Resistance

Enterobacter aerogenes is known for its ability to develop resistance to multiple antibiotics. It possesses several mechanisms of resistance, including the production of beta-lactamases, efflux pumps, and alterations in porin channels.

The emergence of carbapenem-resistant Enterobacteriaceae (CRE), including E. aerogenes, poses a significant challenge in clinical settings. The resistance to carbapenems is often mediated by the production of carbapenemases, such as Klebsiella pneumoniae carbapenemase (KPC) and New Delhi metallo-beta-lactamase (NDM).

Clinical Management

The management of infections caused by Enterobacter aerogenes involves the use of appropriate antimicrobial therapy based on susceptibility testing. Due to the potential for multidrug resistance, treatment options may be limited, and combination therapy may be required.

In addition to antimicrobial therapy, infection control measures are crucial in preventing the spread of E. aerogenes in healthcare settings. These measures include hand hygiene, isolation precautions, and environmental cleaning.

Prevention

Preventing infections caused by Enterobacter aerogenes involves both individual and institutional strategies. Healthcare facilities should implement strict infection control protocols, including the use of personal protective equipment (PPE) and antimicrobial stewardship programs.

Patients and healthcare workers should adhere to hand hygiene practices to reduce the transmission of the bacterium. Monitoring and surveillance of antibiotic resistance patterns are also essential in guiding treatment and prevention strategies.

See Also

• Enterobacteriaceae
• Nosocomial infection
• Antibiotic resistance

External Links

• Centers for Disease Control and Prevention - Carbapenem-resistant Enterobacteriaceae (CRE)
• World Health Organization - Antimicrobial Resistance